A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults
NCT ID: NCT05807490
Last Updated: 2024-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
86 participants
INTERVENTIONAL
2023-04-05
2024-07-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of Part A of this study is to learn about the safety, tolerability, and how PF-07328948 is processed by the body when multiple doses of PF-07328948 are given to healthy participants.
The purpose of Part B of this study is to understand the amount of PF-07328948 that would be available in the body after taking a single pill. The amount will be compared to the amount of PF-07328948 in a suspension in healthy adults.
Part B will be conducted if the results of Part A support further study of PF-07328948.
The study is seeking participants who:
* are females who are not able to give birth to a child of 18 years of age or older.
* are males of 18 years of age or older.
* have a BMI of 20.0 to 35.0 kg/m2.
* have total body weight of more than 50 kg (110 lbs).
Participants in Part A will be randomly selected to receive either PF-07328948 or placebo (a pill that has no medicine in it).
Participants in Part B will receive PF-07328948 as suspension and tablet form, both taken by mouth after food or during fasting.
For a given participant in Part A, the total study is going to last up to about 12 weeks. This includes from the time of selection till the last follow-up phone call. The participants will be selected if they are fit for the study 28 days before the first dose of the study medicines. Participants who are selected will be admitted to the study site on Day -2 for around 19 days. Following discharge, participants will return for an on-site follow-up visit 7 to 10 days after receiving the final dose of the study medicine. The follow-up contact may be via a telephone call and will happen 28 to 35 days after the final dose of study medicine is given.
For a given participant in Part B, the total study is going to last up to about 10-12 weeks. Participants will stay overnight at the CRU for 23 days (Sequence 1) or 18 days (Sequence 2), starting with check-in. In Sequence 1, there will be a minimum of 10 days between doses in Period 1 and 2, and at least 7 days between doses in Period 2 and Period 3. In Sequence 2, there will be a minimum of 7 days between each dose.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults
NCT05907395
A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 Are Tolerated and Act in the Body in Healthy Adults.
NCT06532383
Study Of Single And Multiple Ascending Doses Of PF-07054894 In Healthy Adult Participants
NCT04388878
A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults
NCT06137729
A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults
NCT05890105
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PF-07328948 and Placebo (Cohort 1)
Dose level 1: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
PF-07328948
PF-07328948 will be administered as oral suspensions every 12 hour (BID) over 14 days
Placebo
Placebo will be administered as oral suspensions BID over 14 days
PF-07328948 and Placebo (Cohort 2)
Dose level 2: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
PF-07328948
PF-07328948 will be administered as oral suspensions daily (QD) over 14 days
Placebo
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948 and Placebo (Cohort 3)
Dose level 3: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
PF-07328948
PF-07328948 will be administered as oral suspensions every QD over 14 days
Placebo
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948 and Placebo (Cohort 4)
Dose level 4: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
PF-07328948
PF-07328948 will be administered as oral suspensions QD over 14 days
Placebo
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948 and Placebo (Cohort 5)
Dose level 5: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
PF-07328948
PF-07328948 will be administered as oral suspensions QD over 14 days
Placebo
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948 and Placebo (Cohort 10)
Optional cohort - Multiple dose administration of PF-07328948 and placebo over 14 days in healthy Japanese participants; 5 participants will receive PF-07328948 and 1 will receive placebo
PF-07328948
PF-07328948 will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
Placebo
Placebo will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
PF-07328948
PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
PF-07328948 and Placebo (Cohort 7)
Dose level 7: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
PF-07328948
PF-07328948 will be administered as oral suspensions QD over 14 days
Placebo
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948 and Placebo (Cohort 8)
Optional cohort - Dose level TBD. Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
PF-07328948
PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
Placebo
Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
PF-07328948 oral tablet and oral suspension (Cohort 11)
Assessment of relative bioavailability PF-07328948 oral tablet compared to PF-07328948 oral suspension under fed and fasted condition; 12 participants will be enrolled, and 6 participants randomized to 1 of 2 sequences
PF-07328948
Single doses of PF-07328948 will be administered as oral suspension (single dose) and oral tablet (single dose) under fed and fasted condition
PF-07328948 and Placebo (Cohort 6)
Dose level 6: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
PF-07328948
PF-07328948 will be administered as oral suspensions QD over 14 days
Placebo
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948 and Placebo (Cohort 9)
Optional cohort - Dose level TBD. Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo
PF-07328948
PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
Placebo
Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-07328948
PF-07328948 will be administered as oral suspensions every 12 hour (BID) over 14 days
Placebo
Placebo will be administered as oral suspensions BID over 14 days
PF-07328948
PF-07328948 will be administered as oral suspensions daily (QD) over 14 days
Placebo
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948
PF-07328948 will be administered as oral suspensions every QD over 14 days
Placebo
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948
PF-07328948 will be administered as oral suspensions QD over 14 days
Placebo
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948
PF-07328948 will be administered as oral suspensions QD over 14 days
Placebo
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948
PF-07328948 will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
Placebo
Placebo will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
PF-07328948
PF-07328948 will be administered as oral suspensions QD over 14 days
Placebo
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948
PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
Placebo
Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
PF-07328948
Single doses of PF-07328948 will be administered as oral suspension (single dose) and oral tablet (single dose) under fed and fasted condition
PF-07328948
PF-07328948 will be administered as oral suspensions QD over 14 days
Placebo
Placebo will be administered as oral suspensions QD over 14 days
PF-07328948
PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
Placebo
Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
PF-07328948
PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. BMI of 20.0 to 35.0 kg/m2 and a total body weight \>50 kg (110 lbs) for Part A. BMI of 17.5 to 35.0 kg/m2 and a total body weight \>50 kg (110 lbs) for Part B.
3. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
4. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
Exclusion Criteria
* Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
* History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, HBcAb, or HCVAb. Hepatitis B vaccination is allowed.
2. Part B only: History of irregular bowel movements including irritable bowel syndrome or frequent episodes of diarrhea or constipation (defined as less than 1 bowel movement on average every 2 days) or lactose intolerance.
3. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to COVID-19 pandemic that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
4. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
5. Receipt of a COVID-19 vaccine within 7 days before screening or within 7 days before any visit in which a safety lab is planned. Vaccination with a COVID 19 vaccine that occurs greater than 7 days from either screening or any visit in which a safety lab is planned is permitted.
6. Previous administration with an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
7. Evidence of a prothrombotic state as evidenced by any of the following:
* History of DVT, pulmonary embolism or arterial thrombosis.
* Known genetic predisposition (Factor V Leiden, prothrombin G20210A, Protein C/S deficiency, antithrombin deficiency) based on medical history. Genetic testing at screening is not required.
* ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test if deemed necessary:
* presence of anti-phospholipid antibodies ("Positive" lab result for anticardiolipin, IgA, IgG or IgM)
* Protein C activity \< LLN of laboratory reference range
* Protein S activity \< LLN of laboratory reference range
* Free Protein S antigen \< LLN of laboratory reference range
* Antithrombin activity \< LLN of laboratory reference range
* Positive test for APC resistance (Resistance Ratio \< LLN of laboratory reference range)
* Plasma fibrinogen \> ULN of laboratory reference range
* D-dimer ≥ 500 ng/ml (≥ 0.50 ug/ml)
8. A positive urine drug test.
9. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest.
10. Renal impairment as defined by an eGFR \<75 mL/min/1.73m2 calculated using CKD EPI SCr formulas.
11. Standard 12-lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, QTcF \>450 ms, complete LBBB, signs of an acute or indeterminate age myocardial infarction, STT interval changes suggestive of myocardial ischemia, second- or third-degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If the uncorrected QT interval is \>450 ms, this interval should be rate corrected using the Fridericia method only and the resulting QTcF should be used for decision-making and reporting.
12. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
* AST or ALT level ≥1.5× ULN;
* Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ULN.
13. Prior exposure to PF-07328948.
14. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit, or 3 ounces (90 mL) of wine).
15. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
16. Use of tobacco or nicotine-containing products in excess of the equivalent of 5 cigarettes/day or 2 chews of tobacco/day.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New Haven Clinical Research Unit
New Haven, Connecticut, United States
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-509054-54-00
Identifier Type: OTHER
Identifier Source: secondary_id
C4921002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.